Physician profile
Thomas Scott
NPI 1376500934
$439.41
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $158 · 2020: $119 · 2021: $95.03 · 2022: $67.59.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $85.77 | 2021-2022 | |
| Genzyme Corporation | $71.31 | 2019 | |
| Orthogenrx INC. | $62.18 | 2019-2020 | |
| Pacira Therapeutics, INC. | $52.95 | 2020-2021 | |
| Endo Pharmaceuticals INC. | $38.47 | 2020 | |
| Pacira Pharmaceuticals Incorporated | $36.64 | 2022 | |
| Bioventus LLC | $31.97 | 2019-2020 | |
| Smith+Nephew, INC. | $29.19 | 2019 | |
| Paratek Pharmaceuticals, INC. | $18.28 | 2021 | |
| Zimmer Biomet Holdings, INC. | $12.65 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Scott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.